专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07737166B2 Antifungal bicyclic hetero ring compounds 失效
标题翻译：抗真菌双环杂环化合物
公开(公告)号：US07737166B2
公开(公告)日：2010-06-15
申请号：US12063981
申请日：2006-08-16
申请人： Katsuhiro Kawakami , Kazuo Kanai , Takao Horiuchi , Hiroshi Takeshita , Syozo Kobayashi , Yuichi Sugimoto , Issei Achiwa , Junichi Kuroyanagi
发明人： Katsuhiro Kawakami , Kazuo Kanai , Takao Horiuchi , Hiroshi Takeshita , Syozo Kobayashi , Yuichi Sugimoto , Issei Achiwa , Junichi Kuroyanagi
IPC分类号： C07D417/04 , C07D417/14 , C07D413/14 , C07D413/04 , C07D413/06 , C07D413/12 , C07D403/04 , C07D405/04 , C07D263/56 , C07D263/58 , A61K31/496 , A61K31/4439 , A61K31/427 , A61K31/428 , A61K31/423 , A61K31/454 , A61K31/5377
CPC分类号： C07D413/04 , C07D263/56 , C07D263/58 , C07D403/04 , C07D405/04 , C07D413/14 , C07D417/04 , C07D417/14
摘要： A 1,6-β-glucan synthetase inhibitor is provided, having potent growth inhibition and having excellent safety. A compound is provided, capable of expressing in a wide spectral range and specifically or selectively, an antifungal effect based on its functional mechanism of 1,6-β-glucan synthesis inhibition. Also provided is a drug, a salt or hydrate thereof, especially an antifungal that contains the compound. Concretely, provided is a compound of the following formula (I), its salt or hydrate, and a drug or antifungal containing, as the active ingredient, the compound, its salt or hydrate:
摘要翻译：提供1,6-葡聚糖合成酶抑制剂，具有强大的生长抑制作用并具有优异的安全性。提供了一种化合物，其能够在宽的光谱范围内表达，并且基于其1,6-葡萄糖合成抑制的功能机制，具体或选择性地表达抗真菌作用。还提供了药物，其盐或水合物，特别是含有该化合物的抗真菌剂。具体地，提供下述式（I）的化合物，其盐或水合物，以及含有作为活性成分的化合物，其盐或水合物的药物或抗真菌剂：

2. 发明申请

US20090143353A1 ANTIFUNGAL BICYCLIC HETERO RING COMPOUNDS 失效
标题翻译：抗菌双环异环化合物
公开(公告)号：US20090143353A1
公开(公告)日：2009-06-04
申请号：US12063981
申请日：2006-08-16
申请人： Katsuhiro Kawakami , Kazuo Kanai , Takao Horiuchi , Hiroshi Takeshita , Syozo Kobayashi , Yuichi Sugimoto , Issei Achiwa , Junichi Kuroyanagi
发明人： Katsuhiro Kawakami , Kazuo Kanai , Takao Horiuchi , Hiroshi Takeshita , Syozo Kobayashi , Yuichi Sugimoto , Issei Achiwa , Junichi Kuroyanagi
IPC分类号： A61K31/423 , C07D413/10 , C07D263/54 , A61K31/454 , A61K31/4439 , A61K31/5377 , A61P31/10 , A61K31/496 , A61K31/497 , A61K31/427 , C07D417/14 , C07D413/14
CPC分类号： C07D413/04 , C07D263/56 , C07D263/58 , C07D403/04 , C07D405/04 , C07D413/14 , C07D417/04 , C07D417/14
摘要： A 1,6-β-glucan synthetase inhibitor is provided, having potent growth inhibition and having excellent safety.A compound is provided, capable of expressing in a wide spectral range and specifically or selectively, an antifungal effect based on its functional mechanism of 1,6-β-glucan synthesis inhibition. Also provided is a drug, especially an antifungal that contains the compound, its salt or their hydrate. Concretely, provided are a compound of the following formula (I), its salt or their hydrate, and a drug or antifungal containing, as the active ingredient, the compound, its salt or their hydrate:
摘要翻译：提供了1,6-β葡聚糖合成酶抑制剂，具有强大的生长抑制作用并且具有优异的安全性。提供化合物，其能够在宽的光谱范围内表达，并且基于其1,6-β-葡聚糖合成抑制的功能机制具体或选择性地表达抗真菌作用。还提供了药物，特别是含有化合物，其盐或其水合物的抗真菌剂。具体地，提供下式（I）的化合物，其盐或其水合物，以及含有化合物，其盐或其水合物作为活性成分的药物或抗真菌剂：

3. 发明申请

US20100093785A1 DIAMINE DERIVATIVES 审中-公开
标题翻译： DIAMINE衍生物
公开(公告)号：US20100093785A1
公开(公告)日：2010-04-15
申请号：US12259496
申请日：2008-12-30
申请人： Toshiharu Ohta , Satoshi Komoriya , Toshiharu Yoshino , Kouichi Uoto , Yumi Nakamoto , Hiroyuki Naito , Akiyoshi Mochizuki , Tsutomu Nagata , Hideyuki Kanno , Noriyasu Haginoya , Kenji Yoshikawa , Masatoshi Nagamochi , Syozo Kobayashi , Makoto Ono
发明人： Toshiharu Ohta , Satoshi Komoriya , Toshiharu Yoshino , Kouichi Uoto , Yumi Nakamoto , Hiroyuki Naito , Akiyoshi Mochizuki , Tsutomu Nagata , Hideyuki Kanno , Noriyasu Haginoya , Kenji Yoshikawa , Masatoshi Nagamochi , Syozo Kobayashi , Makoto Ono
IPC分类号： A61K31/437
CPC分类号： C07D487/04 , A61K31/428 , A61K31/429 , A61K31/4365 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4545 , C07D209/42 , C07D401/12 , C07D401/14 , C07D417/12 , C07D417/14 , C07D495/04 , C07D498/04 , C07D513/04 , C07D513/14 , C07K5/06191 , C07K5/0827
摘要： A compound represented by the general formula (1): -Q1-Q2-T0-N(R1)-Q3-(R2)T1Q4 (1) wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof.The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.
摘要翻译：由通式（1）表示的化合物：-Q1-Q2-T0-N（R1）-Q3-（R2）T1Q4（1）其中R1和R2是氢原子等; Q1是可以被取代的饱和或不饱和的5或6元环烃基，等等; Q2是单键等; Q 3为Q 5为碳原子数1〜8的亚烷基等的基团。并且T0和T1是羰基等; 其盐，其溶剂合物或其N-氧化物。该化合物可用作预防和/或治疗脑梗塞，脑栓塞，心肌梗死，心绞痛，肺梗塞，肺栓塞，Buerger病，深静脉血栓形成，弥散性血管内凝血综合征，瓣膜或关节置换后血栓形成，血管成形术后的血栓形成和再闭塞，全身炎症反应综合征（SIRS），多器官功能障碍综合征（MODS），体外循环期间的血栓形成或血液抽血时的凝血。

4. 发明申请

US20080015215A1 DIAMINE DERIVATIVES 审中-公开
标题翻译： DIAMINE衍生物
公开(公告)号：US20080015215A1
公开(公告)日：2008-01-17
申请号：US11850788
申请日：2007-09-06
申请人： Toshiharu Ohta , Satoshi Komoriya , Toshiharu Yoshino , Kouichi Uoto , Yumi Nakamoto , Hiroyuki Naito , Akiyoshi Mochizuki , Tsutomu Nagata , Hideyuki Kanno , Noriyasu Haginoya , Kenji Yoshikawa , Masatoshi Nagamochi , Syozo Kobayashi , Makoto Ono
发明人： Toshiharu Ohta , Satoshi Komoriya , Toshiharu Yoshino , Kouichi Uoto , Yumi Nakamoto , Hiroyuki Naito , Akiyoshi Mochizuki , Tsutomu Nagata , Hideyuki Kanno , Noriyasu Haginoya , Kenji Yoshikawa , Masatoshi Nagamochi , Syozo Kobayashi , Makoto Ono
IPC分类号： A61K31/4365 , A61P43/00 , A61P7/00 , A61P9/00
CPC分类号： C07D487/04 , A61K31/428 , A61K31/429 , A61K31/4365 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4545 , C07D209/42 , C07D401/12 , C07D401/14 , C07D417/12 , C07D417/14 , C07D495/04 , C07D498/04 , C07D513/04 , C07D513/14 , C07K5/06191 , C07K5/0827
摘要： A compound represented by the general formula (1): Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4 (1) wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.
摘要翻译：由通式（1）表示的化合物：<？in-line-formula description =“In-line Formulas”end =“lead”？> Q ^{1 -N（R 1） - N（R 2） - N（R 2） - T （1）<？in-line-formula description =“In-line Formulas”end =“tail”？>其中R 1 < / SUP>和R 2是氢原子等; Q 1是可被取代的饱和或不饱和的5或6元环烃基，等等; Q 2是单键等; Q 3是其中Q 5是具有1〜8个碳原子的亚烷基等的基团; T 0和T 1是羰基等; 其盐，其溶剂合物或其N-氧化物。该化合物可用作预防和/或治疗脑梗塞，脑栓塞，心肌梗死，心绞痛，肺梗塞，肺栓塞，Buerger病，深静脉血栓形成，弥散性血管内凝血综合征，瓣膜或关节置换后血栓形成，血管成形术后的血栓形成和再闭塞，全身炎症反应综合征（SIRS），多器官功能障碍综合征（MODS），体外循环期间的血栓形成或血液抽血时的凝血。}

5. 发明申请

US20050119486A1 Diamine derivatives 有权
标题翻译：二胺衍生物
公开(公告)号：US20050119486A1
公开(公告)日：2005-06-02
申请号：US10481262
申请日：2002-03-20
申请人： Toshiharu Ohta , Satoshi Komoriya , Toshiharu Yoshino , Kouichi Uoto , Yumi Nakamoto , Hiroyuki Naito , Akiyoshi Mochizuki , Tsutomu Nagata , Hideyuki Kanno , Noriyasu Haginoya , Kenji Yoshikawa , Masatoshi Nagamochi , Syozo Kobayashi , Makoto Ono
发明人： Toshiharu Ohta , Satoshi Komoriya , Toshiharu Yoshino , Kouichi Uoto , Yumi Nakamoto , Hiroyuki Naito , Akiyoshi Mochizuki , Tsutomu Nagata , Hideyuki Kanno , Noriyasu Haginoya , Kenji Yoshikawa , Masatoshi Nagamochi , Syozo Kobayashi , Makoto Ono
IPC分类号： C07D401/12 , A61K20060101 , A61P20060101 , A61P7/02 , A61P9/00 , A61P9/10 , A61P29/00 , C07D20060101 , C07D209/42 , C07D401/14 , C07D417/12 , C07D417/14 , C07D487/04 , C07D495/04 , C07D498/04 , C07D513/04 , C07D513/14 , C07D519/00 , C07K5/06 , C07K5/08 , C07D405/00
CPC分类号： C07D487/04 , A61K31/428 , A61K31/429 , A61K31/4365 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4545 , C07D209/42 , C07D401/12 , C07D401/14 , C07D417/12 , C07D417/14 , C07D495/04 , C07D498/04 , C07D513/04 , C07D513/14 , C07K5/06191 , C07K5/0827
摘要： A compound represented by the general formula (1): Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4 (1) wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.
摘要翻译：由通式（1）表示的化合物：<？in-line-formula description =“In-line Formulas”end =“lead”？> Q ^{1 -N（R 1） - N（R 2） - N（R 2） - T （1）<？in-line-formula description =“In-line Formulas”end =“tail”？>其中R 1 < / SUP>和R 2是氢原子等; Q 1是可被取代的饱和或不饱和的5或6元环烃基，等等; Q 2是单键等; Q 3是其中Q 5是具有1〜8个碳原子的亚烷基等的基团; T 0和T 1是羰基等; 其盐，其溶剂合物或其N-氧化物。该化合物可用作预防和/或治疗脑梗塞，脑栓塞，心肌梗死，心绞痛，肺梗塞，肺栓塞，Buerger病，深静脉血栓形成，弥散性血管内凝血综合征，瓣膜或关节置换后血栓形成，血管成形术后的血栓形成和再闭塞，全身炎症反应综合征（SIRS），多器官功能障碍综合征（MODS），体外循环期间的血栓形成或血液抽血时的凝血。}

6. 发明授权

US06747023B1 Sulfonyl derivatives 失效
标题翻译：磺酰基衍生物
公开(公告)号：US06747023B1
公开(公告)日：2004-06-08
申请号：US09762888
申请日：2001-02-12
申请人： Syozo Kobayashi , Satoshi Komoriya , Noriyasu Haginoya , Masanori Suzuki , Toshiharu Yoshino , Takayasu Nagahara , Tsutomu Nagata , Haruhiko Horino , Masayuki Ito , Akiyoshi Mochizuki
发明人： Syozo Kobayashi , Satoshi Komoriya , Noriyasu Haginoya , Masanori Suzuki , Toshiharu Yoshino , Takayasu Nagahara , Tsutomu Nagata , Haruhiko Horino , Masayuki Ito , Akiyoshi Mochizuki
IPC分类号： C07D51304
CPC分类号： C07D207/08 , C07D207/12 , C07D207/22 , C07D211/34 , C07D211/70 , C07D213/56 , C07D213/61 , C07D213/73 , C07D213/75 , C07D213/82 , C07D213/84 , C07D213/89 , C07D233/18 , C07D233/64 , C07D233/88 , C07D239/42 , C07D239/48 , C07D243/08 , C07D277/40 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/04 , C07D405/12 , C07D409/04 , C07D409/12 , C07D409/14 , C07D417/04 , C07D417/12 , C07D417/14
摘要： Described in the present invention are a sulfonyl derivative represented by the following formula (I): Q1—Q2—T1—Q3—SO2—QA (I) [wherein Q1 represents a saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group, 5- or 6-membered heterocyclic group, dicyclic fused ring or tricyclic fused ring group which may have a substituent; Q2 represents a single bond, an oxygen atom, a sulfur atom, a linear or branched C1-6 alkylene group or the like; QA represents an arylalkenyl group which may have a substituent or a heteroarylalkenyl group which may have a substituent; and T1 represents a carbonyl group or the like] and a medicament comprising the same. The compound has strong FXa inhibitory action, provides prompt, sufficient and long-lasting anti-thrombus effects when orally administered, and has low side effects and is therefore useful as an excellent anticoagulant.
摘要翻译：在本发明中描述的是由下式（I）表示的磺酰基衍生物：其中Q 1表示饱和或不饱和的5或6元环烃基，5或6元杂环基，双环稠合可以具有取代基的环或三环稠环; Q 2表示单键，氧原子，硫原子，直链或支链C 1-6亚烷基等; Q表示芳基烯基其可以具有取代基或可以具有取代基的杂芳基烯基; 和T 1表示羰基等]和包含该羰基的药物。该化合物具有强的FXa抑制作用，在口服给药时提供及时，充足和持久的抗血栓作用，副作用小，因此可用作优异的抗凝血剂。

7. 发明授权

US07576135B2 Diamine derivatives 有权
标题翻译：二胺衍生物
公开(公告)号：US07576135B2
公开(公告)日：2009-08-18
申请号：US10540259
申请日：2003-12-25
申请人： Toshiharu Ohta , Satoshi Komoriya , Toshiharu Yoshino , Kouichi Uoto , Yumi Nakamoto , Hiroyuki Naito , Akiyoshi Mochizuki , Tsutomu Nagata , Hideyuki Kanno , Noriyasu Haginoya , Kenji Yoshikawa , Masatoshi Nagamochi , Syozo Kobayashi , Makoto Ono
发明人： Toshiharu Ohta , Satoshi Komoriya , Toshiharu Yoshino , Kouichi Uoto , Yumi Nakamoto , Hiroyuki Naito , Akiyoshi Mochizuki , Tsutomu Nagata , Hideyuki Kanno , Noriyasu Haginoya , Kenji Yoshikawa , Masatoshi Nagamochi , Syozo Kobayashi , Makoto Ono
IPC分类号： A61K31/13
CPC分类号： C07D498/04 , C07D213/75 , C07D401/12 , C07D401/14 , C07D409/04 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D513/14 , C07D519/00
摘要： A compound represented by formula (1): Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4 (1) [wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 represents the following group: (wherein Q5 is an alkylene group having 1 to 8 carbon atoms, or the like); and T0 and T1 are carbonyl groups or the like], a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.
摘要翻译： Q1-Q2-T0-N（R1）-Q3-N（R2）-T1由式（1）表示的化合物：<？in-line-formula description =“In-line formula”end =“lead” -Q4（1）<？in-line-formula description =“In-line Formulas”end =“tail”？> [其中R1和R2是氢原子等; Q1是可以被取代的饱和或不饱和的5或6元环烃基，等等; Q2是单键等; Q3表示以下基团：（其中Q5为碳原子数为1〜8的亚烷基等）; 并且T0和T1是羰基等]，其盐，其溶剂合物或其N-氧化物。该化合物可用作预防和/或治疗脑梗塞，脑栓塞，心肌梗死，心绞痛，肺梗塞，肺栓塞，Buerger病，深静脉血栓形成，弥散性血管内凝血综合征，人工瓣膜或关节后血栓形成血管成形术后的替代，血栓形成和再闭塞，全身炎症反应综合征（SIRS），多器官功能障碍综合征（MODS），体外循环期间的血栓形成或血液抽血时的凝血。

8. 发明申请

US20050020645A1 Diamine derivatives 有权
标题翻译：二胺衍生物
公开(公告)号：US20050020645A1
公开(公告)日：2005-01-27
申请号：US10773344
申请日：2004-02-09
申请人： Toshiharu Ohta , Satoshi Komoriya , Toshiharu Yoshino , Kouichi Uoto , Yumi Nakamoto , Hiroyuki Naito , Akiyoshi Mochizuki , Tsutomu Nagata , Hideyuki Kanno , Noriyasu Haginoya , Kenji Yoshikawa , Masatoshi Nagamochi , Syozo Kobayashi , Makoto Ono
发明人： Toshiharu Ohta , Satoshi Komoriya , Toshiharu Yoshino , Kouichi Uoto , Yumi Nakamoto , Hiroyuki Naito , Akiyoshi Mochizuki , Tsutomu Nagata , Hideyuki Kanno , Noriyasu Haginoya , Kenji Yoshikawa , Masatoshi Nagamochi , Syozo Kobayashi , Makoto Ono
IPC分类号： C07D209/42 , C07D513/04 , A61K31/44 , A61K31/40
CPC分类号： C07D513/04 , C07D209/42
摘要： A compound represented by the general formula (1): Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4 (1) wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.
摘要翻译：由通式（1）表示的化合物：Q 1 -Q 2 -N（R 1）-Q 3 -N（R 2）-T 1 -Q 4（1）其中R 1和R 2都是氢原子等; Q 1是可被取代的饱和或不饱和的5或6元环烃基，等等; Q 2是单键等; Q 3为Q 5为碳原子数1〜8的亚烷基等的基团， T 0和T 1是羰基等; 其盐，其溶剂合物或其N-氧化物。该化合物可用作预防和/或治疗脑梗塞，脑栓塞，心肌梗死，心绞痛，肺梗塞，肺栓塞，Buerger病，深静脉血栓形成，弥散性血管内凝血综合征，瓣膜或关节置换后血栓形成，血管成形术后的血栓形成和再闭塞，全身炎症反应综合征（SIRS），多器官功能障碍综合征（MODS），体外循环期间的血栓形成或血液抽血时的凝血。

9. 发明授权

US4430538A High-frequency heating device 失效
标题翻译：高频加热装置
公开(公告)号：US4430538A
公开(公告)日：1984-02-07
申请号：US294419
申请日：1981-08-19
申请人： Yukio Suzuki , Syozo Kobayashi
发明人： Yukio Suzuki , Syozo Kobayashi
IPC分类号： H05B6/74 , H05B6/80 , H05B6/72
CPC分类号： H05B6/725 , H05B6/74
摘要： A high-frequency heating device comprises a rotating disk including a base plate made of a material having low dielectric loss and arranged above in a heating chamber to rotate around its center axis, and a plurality of high-frequency screening pieces each arranged on the base plate and defining an exciting opening therebetween which has plural portions extending radially from the center axis to the outer circumference of the base plate. The rotating disk is driven by a motor or a part of air flow for cooling a magnetron whereby high frequency energy generated by a magnetron is introduced into the heating chamber through a waveguide and the exciting opening.
摘要翻译：一种高频加热装置，包括：旋转盘，其包括由介电损耗低的材料制成的基板，并且布置在加热室中以围绕其中心轴线旋转;以及多个高频屏蔽件，每个高频屏蔽件均布置在基座并且在它们之间限定一个激励开口，其具有从基板的中心轴线到外周径向延伸的多个部分。旋转盘由马达或气流的一部分驱动，用于冷却磁控管，由磁控管产生的高频能量通过波导管和激励开口引入加热室。

10. 发明申请

US20090281074A1 DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM 审中-公开
标题翻译：药物组合物和预防和治疗血栓形成或栓塞的方法
公开(公告)号：US20090281074A1
公开(公告)日：2009-11-12
申请号：US12250586
申请日：2008-10-14
申请人： Toshiharu OHTA , Satoshi Komoriya , Toshiharu Yoshino , Kouichi Outo , Yumi Nakamoto , Hiroyuki Naito , Akiyoshi Mochizuki , Tsutomu Nagata , Hideyuki Kanno , Noriyasu Haginoya , Kenji Yoshikawa , Masatoshi Nagamochi , Syozo Kobayashi , Makoto Ono
发明人： Toshiharu OHTA , Satoshi Komoriya , Toshiharu Yoshino , Kouichi Outo , Yumi Nakamoto , Hiroyuki Naito , Akiyoshi Mochizuki , Tsutomu Nagata , Hideyuki Kanno , Noriyasu Haginoya , Kenji Yoshikawa , Masatoshi Nagamochi , Syozo Kobayashi , Makoto Ono
IPC分类号： A61K31/397 , A61K31/437 , A61K31/502 , A61K31/5377 , A61K31/55
CPC分类号： C07D498/04 , C07D213/75 , C07D401/12 , C07D401/14 , C07D409/04 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D513/14 , C07D519/00
摘要： Drug compositions containing a substituted diamine compound represented by formula (1): Q1-Q2-r-N(R1)-Q3-N(R2) (1) wherein Q3 represents the following group wherein Q5 represents an alkylene group having 4 carbon atoms, R3 represents a hydrogen atom, and R4 represents a 3-6 membered heterocyclic group which may be substituted; are useful for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.
摘要翻译：含有式（1）表示的取代二胺化合物的药物组合物：Q1-Q2-rN（R1）-Q3-N（R2）（1）其中Q3表示以下基团，其中Q5表示具有4个碳原子的亚烷基，R3 表示氢原子，R4表示可以被取代的3-6元杂环基; 可用于预防和/或治疗脑梗死，脑栓塞，心肌梗死，心绞痛，肺梗塞，肺栓塞，Buerger病，深静脉血栓形成，弥散性血管内凝血综合征，人工瓣膜或关节置换后血栓形成，血栓形成和血管成形术后再闭塞，全身炎症反应综合征（SIRS），多器官功能障碍综合征（MODS），体外循环期间的血栓形成或血液抽血时的凝血。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式